2023
Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors
Sella T, Zheng Y, Rosenberg S, Ruddy K, Gelber S, Tamimi R, Peppercorn J, Schapira L, Borges V, Come S, Carey L, Winer E, Partridge A. Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors. Npj Breast Cancer 2023, 9: 31. PMID: 37185922, PMCID: PMC10130172, DOI: 10.1038/s41523-023-00529-y.Peer-Reviewed Original ResearchBreast cancer survivorsYoung Women's Breast Cancer StudyYoung breast cancer survivorsAdjuvant endocrine therapyCancer survivorsBreast Cancer StudyEndocrine therapyBreast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerAromatase inhibitor monotherapyMulticenter prospective cohortPotential sociodemographic disparitiesRecurrence/deathRisk-based careReceipt of chemotherapyNon-Hispanic whitesWarrants further investigationPostmenopausal womenInhibitor monotherapyProspective cohortMultivariable analysisEligible participantsMean ageLongitudinal cohort
2018
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal Of Medicine 2018, 379: 122-137. PMID: 29863451, PMCID: PMC6193457, DOI: 10.1056/nejmoa1803164.Peer-Reviewed Original ResearchConceptsTamoxifen plus ovarian suppressionTamoxifen-alone groupOvarian suppressionPremenopausal womenBreast cancerAdverse eventsOverall survivalDisease-free survival ratesOvarian Function TrialYears of tamoxifenAdjuvant endocrine therapyHigher adverse eventsReceipt of chemotherapyPremenopausal breast cancerLow recurrence rateAromatase inhibitor exemestaneUse of exemestaneSuppression groupExemestane TrialDistant recurrenceEndocrine therapyRecurrence rateGrade 3ExemestaneTamoxifen
2014
Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study
Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. Journal Of Clinical Oncology 2014, 32: 2142-2150. PMID: 24888816, PMCID: PMC4076026, DOI: 10.1200/jco.2013.53.1608.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansMastectomy, SegmentalMiddle AgedNeoplasm StagingPrognosisProspective StudiesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTrastuzumabTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesConceptsDistant relapse-free survivalBN0M0 breast cancerHER2-negative tumorsBreast cancerT1a tumorsCohort studyT1b tumorsSurvival outcomesHR-positive/HER2-negative tumorsTumor subtypesNational Comprehensive Cancer Network databaseHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusHER2-negative breast cancerNode-negative breast cancerHormone receptorsConsideration of chemotherapyHER2-negative diseasePercent of patientsReceipt of chemotherapyNonrandomized cohort studyProspective cohort studyRelapse-free survivalRate of recurrenceMulti-institutional study
2009
Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making
Gold J, Najita J, Lester S, Richardson A, Morganstern D, Chen W, Partridge A, Krop I, Winer E, Burstein H. Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. Journal Of Clinical Oncology 2009, 27: 572-572. DOI: 10.1200/jco.2009.27.15_suppl.572.Peer-Reviewed Original ResearchEarly-stage breast cancerOncotype DX recurrence scoreRecurrence scoreDX recurrence scoreAdjuvant chemotherapyClinical factorsTumor gradeChemotherapy decisionsBreast cancerMultivariable logistic regression modelStandard clinicopathologic dataProgesterone receptor expressionReceipt of chemotherapyAdjuvant chemotherapy decisionsLow recurrence scoreHigh recurrence scoreStage breast cancerSingle academic institutionLikelihood of benefitStandard clinical factorsElectronic medical recordsLogistic regression modelsChemotherapy recommendationsMenopausal statusChemotherapy administration